Neuroendocrine predictors of the evolution of depression

Depression is both clinically and biologically a heterogeneous entity Despite advances in psychopharmacology a significant proportion of depressed patients either continue to have residual symptoms or do not respond to antidepressants, It has therefore become essential to determine parameters (or predictors) that would rationalize the therapeutic choice, taking into account not only the clinical features, but also the “biological state, ” which is a major determinant in the antidepressant response. Such predictors can derive from bioclinical correlates and, in this context, the neuroendocrine strategy appears particularly suited. Numerous studies have investigated neuroendocrine parameters - derived mainly from dynamic challenge tests - in order to (i) determine the predictive profiles of good clinical responders to given anti-depressants; (ii) monitor the progression of markers in parallel with the clinical outcome; and (Hi) evaluate “in vivo” in humans the mechanisms of action of antidepressant compounds (before, during, and after treatment). This article does not attempt to be exhaustive, but rather uses selected examples to illustrate the usefulness of the investigation of the adrenal and thyroid axes and the assessment of central serotonergic, noradrenergic, and dopaminergic systems by means of neuroendocrine tests. Given methodological constraints, most of these investigations - except for baseline hormone values and the dexamethasone suppression test - cannot be used routinely in psychiatry Despite these limitations, the neuroendocrine strategy still offers new insights in biology and the treatment of depression. Its possible expansion depends mainly on the development of specific agonists or antagonists for better investigation of the receptors supposedly involved in the pathophysiology of depression. These investigations will help define more homogeneous subgroups from a bioclinical and therapeutic viewpoint.